A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes
Trial Parameters
Brief Summary
Exploring the Clinical Application Value of Contrast Enhancement Features in CE-EBUS Images for the Diagnosis of Pulmonary Lesions and Intrapulmonary Lymph Nodes
Eligibility Criteria
Inclusion Criteria: * Age \>18 years old； * Enlargement of at least one intrathoracic LN (short diameter \> 1 cm) or central parenchymal lung lesions adjacent to the airway detected on chest CT, or increased fluorodeoxyglucose uptake in at least one intrathoracic lymph node on PET / CT (standardized uptake value \> 2.5)； * CP-EBUS-TBNA is required to determine the diagnosis or staging, the patient agreed to undergo CE-EBUS, and there were no contraindications to EBUS-TBNA; * Patients who have good compliance and sign informed consent. Exclusion Criteria: * Patients with known hypersensitivity to ultrasound contrast components; * Patients with severe pulmonary hypertension (pulmonary artery pressure \> 90 mmHg); * Patients with angina pectoris, acute coronary syndrome, clinically unstable ischemic heart disease, heart failure, cardiac dysfunction, and cardiac disease with right-to-left shunting; * Patients with uncontrolled essential hypertension and adults with respiratory distress syn